Prognostic performance of different lymph node staging systems after curative intent resection for gastric adenocarcinoma

Annals of Surgery

Volumn 262, Issue 6, 2015, Pages 991-998

  Spolverato, Gaya ^a   Ejaz, Aslam ^a   Kim, Yuhree ^a   Squires, Malcolm H ^b   Poultsides, George ^c   Fields, Ryan C ^d   Bloomston, Mark ^e   Weber, Sharon M ^f   Votanopoulos, Konstantinos ^g   Acher, Alexandra W ^g   Jin, Linda X ^d   Hawkins, William G ^c   Schmidt, Carl ^e   Kooby, David A ^b   Worhunsky, David ^c   Saunders, Neil ^g   Cho, Clifford S ^f   Levine, Edward A ^g   Maithel, Shishir K ^b   Pawlik, Timothy M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c STANFORD UNIVERSITY   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e OHIO STATE UNIVERSITY   (United States)

^f UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^g WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

AJCC staging; Gastric adenocarcinoma; LNR; LODDS; Lymph node

Indexed keywords

ADULT; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; FEMALE; HUMAN; LONG TERM SURVIVAL; LYMPH NODE METASTASIS; LYMPH NODE RATIO; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; RISK ASSESSMENT; STOMACH ADENOCARCINOMA; ADENOCARCINOMA; AGED; COMPARATIVE STUDY; EVALUATION STUDY; FOLLOW UP; GASTRECTOMY; LYMPH NODE; LYMPH NODE DISSECTION; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; STOMACH NEOPLASMS; SURVIVAL;

ADENOCARCINOMA; ADULT; AGED; FEMALE; FOLLOW-UP STUDIES; GASTRECTOMY; HUMANS; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; STOMACH NEOPLASMS; SURVIVAL ANALYSIS;

EID: 84948715545     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0000000000001040     Document Type: Article

References (57)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
2. Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol. 2006;12:354-362.
3. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11-30.
4. Arrington AK, Nelson R, Patel SS, et al. Timing of chemotherapy and survival in patients with resectable gastric adenocarcinoma. World J Gastrointest Surg. 2013;5:321-328.
5. Berardi R, Scartozzi M, Romagnoli E, et al. Gastric cancer treatment: a systematic review. Oncol Rep. 2004;11:911-916.
6. Degiuli M, Sasako M, Ponti A, et al. Randomized clinical trial comparing survival after D1 or D2 gastrectomy for gastric cancer. Br J Surg. 2014;101: 23-31.
7. Dickson JL, Cunningham D. Systemic treatment of gastric cancer. Eur J Gastroenterol Hepatol. 2004;16:255-263.
8. Hirota WK, Zuckerman MJ, Adler DG, et al. ASGE guideline: the role of endoscopy in the surveillance of premalignant conditions of the upper GI tract. Gastrointest Endosc. 2006;63:570-580.
9. Kim JP, Lee JH, Kim SJ, et al. Clinicopathologic characteristics and prognostic factors in 10 783 patients with gastric cancer. Gastric Cancer. 1998;1:125-133.
10. Isozaki H, Okajima K, Fujii K, et al. Effectiveness of paraaortic lymph node dissection for advanced gastric cancer. Hepatogastroenterology. 1999;46: 549-554.
11. Posteraro B, Persiani R, Dall'armi V, et al. Prognostic factors and outcomes in Italian patients undergoing curative gastric cancer surgery. Eur J Surg Oncol. 2013.
12. Sakuramoto S, Kikuchi S, Futawatari N, et al. Laparoscopy-assisted pancreas-and spleen-preserving total gastrectomy for gastric cancer as compared with open total gastrectomy. Surg Endosc. 2009;23:2416-2423.
13. Songun I, Putter H, Kranenbarg EM, et al. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 2010;11:439-449.
14. de Jong MC, Nathan H, Sotiropoulos GC, et al. Intrahepatic cholangiocarci-noma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol. 2011;29:3140-3145.
15. Gleisner AL, Mogal H, Dodson R, et al. Nodal status, number of lymph nodes examined, and lymph node ratio: what defines prognosis after resection of colon adenocarcinoma? J Am Coll Surg. 2013;217:1090-1100.
16. Asiyanbola B, Gleisner A, Herman JM, et al. Determining pattern of recurrence following pancreaticoduodenectomy and adjuvant 5-flurouracil-based chemoradiation therapy: effect of number of metastatic lymph nodes and lymph node ratio. J Gastrointest Surg. 2009;13: 752-759.
17. Slidell MB, Chang DC, Cameron JL, et al. Impact of total lymph node count and lymph node ratio on staging and survival after pancreatectomy for pancreatic adenocarcinoma: a large, population-based analysis. Ann Surg Oncol. 2008;15:165-174.
18. Parsons HM, Tuttle TM, Kuntz KM, et al. Association between lymph node evaluation for colon cancer and node positivity over the past 20 years. JAMA. 2011;306:1089-1097.
19. Baxter NN, Ricciardi R, Simunovic M, et al. An evaluation of the relationship between lymph node number and staging in pT3 colon cancer using population-based data. Dis Colon Rectum. 2010;53:65-70.
20. Hermanek P, Sobin LH. UICC TNM Classification of Malignant Tumors. 4th ed. Berlin, Germany: Springer; 1987.
21. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma-2nd English edition. Gastric Cancer. 1998; 1:10-24.
22. Greene FL, Page DL, Fleming ID, et al. AJCC Cancer Staging Manual. 6th ed. New York, NY: Springer; 2002.
23. Japanese Gastric Cancer A. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011; 14:101-112.
24. Yoo CH, Noh SH, Kim YI, et al. Comparison of prognostic significance of nodal staging between old (4th edition) and new (5th edition) UICC TNM classification for gastric carcinoma. International Union Against Cancer. World J Surg. 1999;23:492-497; discussion 497-498.
25. Nio Y, Yamasawa K, Yamaguchi K, et al. Problems in the N-classification of the new 1997 UICC TNM stage classification for gastric cancer: an analysis of over 10 years' outcome of Japanese patients. Anticancer Res. 2003;23: 697-705.
26. Shen JY, Kim S, Cheong JH, et al. The impact of total retrieved lymph nodes on staging and survival of patients with pT3 gastric cancer. Cancer. 2007;110:745-751.
27. Bouvier AM, Haas O, Piard F, et al. How many nodes must be examined to accurately stage gastric carcinomas? Results from a population based study. Cancer. 2002;94:2862-2866.
28. Lee HK, Yang HK, Kim WH, et al. Influence of the number of lymph nodes examined on staging of gastric cancer. Br J Surg. 2001;88:1408-1412.
29. Ichikura T, Ogawa T, Chochi K, et al. Minimum number of lymph nodes that should be examined for the International Union Against Cancer(American Joint Committee on Cancer TNM classification of gastric carcinoma. World J Surg. 2003;27:330-333.
30. Bertoni E, Zanazzi M, Rosat A, et al. Efficacy and safety of Palmaz stent insertion in the treatment of renal artery stenosis in kidney transplantation. Transpl Int. 2000;13 suppl 1:S425-S430.
31. Marchet A, Mocellin S, Ambrosi A, et al. The prognostic value of N-ratio in patients with gastric cancer: validation in a large, multicenter series. Eur J Surg Oncol. 2008;34:159-165.
32. Marchet A, Mocellin S, Ambrosi A, et al. The ratio between metastatic and examined lymph nodes (N ratio) is an independent prognostic factor in gastric cancer regardless of the type of lymphadenectomy: results from an Italian multicentric study in 1853 patients. Ann Surg. 2007;245:543-552.
33. Wang J, Dang P, Raut CP, et al. Comparison of a lymph node ratio-based staging system with the 7th AJCC system for gastric cancer: analysis of 18, 043 patients from the SEER database. Ann Surg. 2012;255:478-485.
34. Sun Z, Xu Y, Li de M, et al. Log odds of positive lymph nodes: a novel prognostic indicator superior to the number-based and the ratio-based N category for gastric cancer patients with R0 resection. Cancer. 2010;116: 2571-2580.
35. Wang J, Hassett JM, Dayton MT, et al. The prognostic superiority of log odds of positive lymph nodes in stage III colon cancer. J Gastrointest Surg. 2008;12:1790-1796.
36. Smith DD, Nelson RA, Schwarz RE. A comparison of five competing lymph node staging schemes in a cohort of resectable gastric cancer patients. Ann Surg Oncol. 2014;21:875-882.
37. Liu H, Deng J, Zhang R, et al. The RML of lymph node metastasis was superior to the LODDS for evaluating the prognosis of gastric cancer. Int J Surg. 2013;11:419-424.
38. Xu J, Bian YH, Jin X, et al. Prognostic assessment of different metastatic lymph node staging methods for gastric cancer after D2 resection. World J Gastroenterol. 2013;19:1975-1983.
39. Wang X, Appleby DH, Zhang X, et al. Comparison of three lymph node staging schemes for predicting outcome in patients with gastric cancer. Br J Surg. 2013;100:505-514.
40. Spolverato G, Ejaz A, Kim Y, et al. Rates and patterns of recurrence following curative intent resection for gastric cancer: a united states multi-institutional analysis. J Am Coll Surg. 2014;219:664-675.
41. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer. 2011;14:113-123.
42. Edge S, Bryd DR, Compton CC, et al. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2010.
43. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15:361-387.
44. Sun Z, Zhu GL, Lu C, et al. The impact of N-ratio in minimizing stage migration phenomenon in gastric cancer patients with insufficient number or level of lymph node retrieved: results from a Chinese mono-institutional study in 2159 patients. Ann Oncol. 2009;20:897-905.
45. Allum WH. Optimal surgery for gastric cancer: is more always better? Recent Results Cancer Res. 2012;196:215-227.
46. Siewert JR, Bottcher K, Roder JD, et al. Prognostic relevance of systematic lymph node dissection in gastric carcinoma. German Gastric Carcinoma Study Group. Br J Surg. 1993;80:1015-1018.
47. Wu CW, Hsiung CA, Lo SS, et al. Nodal dissection for patients with gastric cancer: a randomised controlled trial. Lancet Oncol. 2006;7:309-315.
48. Cuschieri A, Weeden S, Fielding J, et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer. 1999;79:1522-1530.
49. Bonenkamp JJ, Hermans J, Sasako M, et al. Extended lymph-node dissection for gastric cancer. N Engl J Med. 1999;340:908-914.
50. Jarnagin WR, Fong Y, Ky A, et al. Liver resection for metastatic colorectal cancer: assessing the risk of occult irresectable disease. J Am Coll Surg. 1999;188:33-42.
51. Roder JD, Bottcher K, Busch R, et al. Classification of regional lymph node metastasis from gastric carcinoma. German Gastric Cancer Study Group. Cancer. 1998;82:621-631.
52. Schwarz RE, Smith DD. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol. 2005;23:5404-5405; author reply 5405.
53. Inoue K, Nakane Y, Iiyama H, et al. The superiority of ratio-based lymph node staging in gastric carcinoma. Ann Surg Oncol. 2002;9:27-34.
54. Yoon SS, Yang HK. Lymphadenectomy for gastric adenocarcinoma: should west meet east? Oncologist. 2009;14:871-882.
55. Chang YJ, Chang YJ, Chen LJ, et al. Evaluation of lymph nodes in patients with colon cancer undergoing colon resection: a population-based study. World J Surg. 2012;36:1906-1914.
56. Zhou Y, Zhang J, Cao S, et al. The evaluation of metastatic lymph node ratio staging system in gastric cancer. Gastric Cancer. 2013;16:309-317.
57. Zeng WJ, Hu WQ, Wang LW, et al. Lymph node ratio is a better prognosticator than lymph node status for gastric cancer: a retrospective study of 138 cases. Oncol Lett. 2013;6:1693-1700.